BlossomHill Therapeutics (NASDAQ:BLSM) Director Carl Gordon Buys 625,000 Shares of Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Director Carl Gordon bought 625,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This trade represents a 29.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

BlossomHill Therapeutics Stock Down 1.7%

Shares of BLSM stock opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a 12 month low of $15.25 and a 12 month high of $17.25.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.